TOP TEN perturbations for 39522_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39522_at
Selected probe(set): 202464_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39522_at (202464_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-5.148801Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
retina pigment epithelium study 1 (adult) / retina pigment epithelium study 1 (fetal)
Relative Expression (log2-ratio):4.18886Number of Samples:2 / 6
Experimental | retina pigment epithelium study 1 (adult) |
Postmortem human native retina pigment epithelium samples from adult individuals. | |
Control | retina pigment epithelium study 1 (fetal) |
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18. |
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):3.9889927Number of Samples:8 / 8
Experimental | PMA; ionomycine study 2 |
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
Control | unstimulated CD4 memory T-cell sample |
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):-3.7842941Number of Samples:6 / 12
Experimental | IL-4; GM-CSF study 1 (late) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
oxyphilic adenoma study 1 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.7517834Number of Samples:4 / 3
Experimental | oxyphilic adenoma study 1 |
Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma). | |
Control | normal kidney tissue (adult) |
Normal adult kidney tissue samples. |
retina pigment epithelium study 2 (fetal) / retina pigment epithelium study 1 (fetal)
Relative Expression (log2-ratio):3.7075548Number of Samples:12 / 6
Experimental | retina pigment epithelium study 2 (fetal) |
Human cultured fetal retina pigment epithelium samples obtained at gestation age between week 16-18. | |
Control | retina pigment epithelium study 1 (fetal) |
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18. |
expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):3.6705341Number of Samples:3 / 4
Experimental | expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) |
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid. | |
Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.6637144Number of Samples:4 / 3
Experimental | renal cell carcinoma study 6 (chromophobe type) |
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC). | |
Control | normal kidney tissue (adult) |
Normal adult kidney tissue samples. |
precursor-B-ALL study 2 (hyperdiploid) / T-ALL study 2
Relative Expression (log2-ratio):3.6442165Number of Samples:27 / 13
Experimental | precursor-B-ALL study 2 (hyperdiploid) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | T-ALL study 2 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG). |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):3.5876122Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |